Recent Updates
Recently added Catalysts
LUCD Positive Sentiment Score: 70/100

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

Key Takeaway: Lucid Diagnostics Inc. has announced a business update conference call scheduled for May 14, 2025, at 8:30 AM ET. The call will feature presentations from CEO Lishan Aklog and CFO Dennis McGrath, who will discuss the company’s operations and first quarter financial results. Lucid is focused on preventing cancer through early detection in patients at risk of esophageal precancer and cancer, emphasizing its EsoGuard Esophageal DNA test. The conference call will be accessible via teleconference and webcast.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lucid Diagnostics will provide important updates on its growth strategy.
  • The upcoming conference call will also discuss the company's first quarter financial results.
  • Lucid's focus on cancer prevention is vital for at-risk patients.

Full Press Release Details

Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 financial results.
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
SOURCE Lucid Diagnostics

21 %

more press release views with

Frequently Asked Questions

When is Lucid Diagnostics' business update conference call?

The conference call is scheduled for May 14, 2025, at 8:30 AM ET.

Who will speak during the conference call?

Lishan Aklog, M.D., and Dennis McGrath will provide updates and financial results.

How can I access the conference call by phone?

U.S. callers should dial 1-800-836-8184; international listeners can call 1-646-357-8785.

Where can I find the webcast of the conference call?

The webcast will be available in the investor relations section of luciddx.com.

What is the focus of Lucid Diagnostics?

Lucid Diagnostics specializes in cancer prevention for patients at risk of esophageal cancer.

Last updated: Apr 30, 2025